Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

371

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Damoctocog alfa pegol (Jivi, Bay94-9027)

Sponsor

Bayer